Lindsey Shapiro, PhD, science writer —

A single injection of STAR-0215, an experimental treatment to prevent swelling attacks in people with hereditary angioedema (HAE), safely led to rapid and sustained inhibition of the kallikrein protein in healthy adults, according to preliminary data from a Phase 1a trial. “STAR-0215 has shown early proof of concept for…

A single dose of the extended-release formulation of PHA121 — an investigational molecule under development for the prevention and treatment of swelling attacks associated with hereditary angioedema (HAE) — led to sustained, therapeutic levels of the medication in the bloodstream of participants. That’s according to promising data from…

A single infusion of the investigational gene therapy NTLA-2002 was well tolerated at two different doses and reduced the number of swelling attacks in people with hereditary angioedema (HAE) by more than 90%, according to interim results from the Phase 1 portion of a Phase 1/2 trial. The…

Off-label prescription of certain medications indicated for hereditary angioedema (HAE) with C1 deficiency to people with other types of angioedema is common, a team of French researchers found. Fewer than 20% of prescriptions for these medications, namely Berinert, Cinryze, Ruconest (conestat alfa), and Firazyr…

A class of medications used to treat diabetes is associated with the occurrence of angioedema, particularly among older adults, a study has found. The use of these medications, called dipeptidyl peptidase-4 inhibitors (DPP-4Is), was linked to the condition in some groups even when patients were not also using a…

Swelling in the hands and feet, as well as elevated blood levels of eosinophils — a type of immune cell — led clinicians to diagnose a Japanese woman with non-episodic angioedema associated with eosinophilia (NEAE), as described in a case report. Distinguishing NEAE from similar conditions is important, the…

One person out of six treated with Ruconest (rhC1INH) for idiopathic non-histaminergic angioedema (InH-AAE) as part of an exploratory study showed a positive clinical response to the medication. The findings may mean that Ruconest is effective in a subset of InH-AAE patients, the researchers noted. The study, “…

Death due to breathing difficulties associated with hereditary angioedema (HAE) remains a concern in Brazil, highlighting that misdiagnosis and a lack of treatment access in lower-income countries may contribute to increased mortality rates, a recent study highlights. While HAE-associated deaths have declined significantly in recent years within high-income countries,…

KVD900, KalVista Pharmaceuticals’ investigational on-demand treatment for swelling attacks in people with hereditary angioedema (HAE), will now be called sebetralstat, the company announced. Sebetralstat will become the nonproprietary nomenclature for the treatment’s active ingredients, meaning that will be the generic name for any medication using the same formulation…

Takhzyro (lanadelumab) led to significant benefits for patients with hereditary angiodema (HAE) in France who received the therapy as part of an early-access program prior to its approval in Europe, a study has found. The treatment “reduced attack rates, improved quality of life, and was generally well tolerated,”…